Terms: = Colorectal cancer AND HRAS, K-ras, 3265, ENSG00000174775, HRAS1, RASH1, c-bas/has, P01112, N-ras AND Clinical Outcome
25 results:
1. Conversion strategies with chemotherapy plus targeted agents for colorectal cancer liver-only metastases: A systematic review.
Bolhuis K; Kos M; van Oijen MGH; Swijnenburg RJ; Punt CJA
Eur J Cancer; 2020 Dec; 141():225-238. PubMed ID: 33189037
[TBL] [Abstract] [Full Text] [Related]
2. The role of miRNA -31-3p and miR-31-5p in the anti-EGFR treatment efficacy of wild-type k-ras metastatic colorectal cancer. Is it really the next best thing in miRNAs?
Sur D; Cainap C; Burz C; Havasi A; Chis IC; Vlad C; Milosevic V; Balacescu O; Irimie A
J BUON; 2019; 24(5):1739-1746. PubMed ID: 31786833
[TBL] [Abstract] [Full Text] [Related]
3. The prognostic significance of p63 cytoplasmic expression in colorectal cancer. An immunohistochemical study.
Albasri AM; Elkablawy MA; Ansari IA; Alhujaily AS; Khalil AA
Saudi Med J; 2019 May; 40(5):432-439. PubMed ID: 31056618
[TBL] [Abstract] [Full Text] [Related]
4. DNA copy number alterations, gene expression changes and disease-free survival in patients with colorectal cancer: a 10 year follow-up.
Bigagli E; De Filippo C; Castagnini C; Toti S; Acquadro F; Giudici F; Fazi M; Dolara P; Messerini L; Tonelli F; Luceri C
Cell Oncol (Dordr); 2016 Dec; 39(6):545-558. PubMed ID: 27709558
[TBL] [Abstract] [Full Text] [Related]
5. Prospective study of a molecular selection profile for RAS wild type colorectal cancer patients receiving irinotecan-cetuximab.
Giampieri R; Mandolesi A; Abouelkhair KM; Loretelli C; Del Prete M; Faloppi L; Maristella B; Ibrahim EM; Scarpelli M; Cascinu S; Scartozzi M
J Transl Med; 2015 May; 13():140. PubMed ID: 25943333
[TBL] [Abstract] [Full Text] [Related]
6. [Correlation analysis between abundance of k-ras mutation in plasma free DNA and its correlation with clinical outcome and prognosis in patients with metastatic colorectal cancer].
Bai YQ; Liu XJ; Wang Y; Ge FJ; Zhao CH; Fu YL; Lin L; Xu JM
Zhonghua Zhong Liu Za Zhi; 2013 Sep; 35(9):666-71. PubMed ID: 24332053
[TBL] [Abstract] [Full Text] [Related]
7. Role of β4 integrin in HER-3-negative, k-ras wild-type metastatic colorectal tumors receiving cetuximab.
Scartozzi M; Giampieri R; Loretelli C; Mandolesi A; del Prete M; Biagetti S; Alfonsi S; Faloppi L; Bianconi M; Bittoni A; Bearzi I; Cascinu S
Future Oncol; 2013 Aug; 9(8):1207-14. PubMed ID: 23617461
[TBL] [Abstract] [Full Text] [Related]
8. Mutant n-ras protects colorectal cancer cells from stress-induced apoptosis and contributes to cancer development and progression.
Wang Y; Velho S; Vakiani E; Peng S; Bass AJ; Chu GC; Gierut J; Bugni JM; Der CJ; Philips M; Solit DB; Haigis KM
Cancer Discov; 2013 Mar; 3(3):294-307. PubMed ID: 23274911
[TBL] [Abstract] [Full Text] [Related]
9. The usability of allele-specific PCR and reverse-hybridization assays for KRAS genotyping in Serbian colorectal cancer patients.
Brotto K; Malisic E; Cavic M; Krivokuca A; Jankovic R
Dig Dis Sci; 2013 Apr; 58(4):998-1003. PubMed ID: 23108567
[TBL] [Abstract] [Full Text] [Related]
10. Phosphorylated AKT and MAPK expression in primary tumours and in corresponding metastases and clinical outcome in colorectal cancer patients receiving irinotecan-cetuximab.
Scartozzi M; Giampieri R; Maccaroni E; Mandolesi A; Biagetti S; Alfonsi S; Giustini L; Loretelli C; Faloppi L; Bittoni A; Bianconi M; Del Prete M; Bearzi I; Cascinu S
J Transl Med; 2012 Apr; 10():71. PubMed ID: 22490361
[TBL] [Abstract] [Full Text] [Related]
11. Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for k-ras wild-type colorectal cancer patients receiving irinotecan-cetuximab.
Scartozzi M; Giampieri R; Maccaroni E; Mandolesi A; Giustini L; Silva R; Zaniboni A; Biscotti T; Biagetti S; Galizia E; Loupakis F; Falcone A; Bearzi I; Cascinu S
Ann Oncol; 2012 Jul; 23(7):1706-12. PubMed ID: 22112971
[TBL] [Abstract] [Full Text] [Related]
12. The role of HER-3 expression in the prediction of clinical outcome for advanced colorectal cancer patients receiving irinotecan and cetuximab.
Scartozzi M; Mandolesi A; Giampieri R; Bittoni A; Pierantoni C; Zaniboni A; Galizia E; Giustini L; Silva RR; Bisonni R; Berardi R; Biscotti T; Biagetti S; Bearzi I; Cascinu S
Oncologist; 2011; 16(1):53-60. PubMed ID: 21212430
[TBL] [Abstract] [Full Text] [Related]
13. Genetic alterations of k-ras may reflect prognosis in stage III colon cancer patients below 60 years of age.
Onozato W; Yamashita K; Yamashita K; Kuba T; Katoh H; Nakamura T; Sato T; Ihara A; Okayasu I; Watanabe M
J Surg Oncol; 2011 Jan; 103(1):25-33. PubMed ID: 21031422
[TBL] [Abstract] [Full Text] [Related]
14. clinical impact of k-ras mutation in colorectal cancer patients treated with adjuvant FOLFOX.
Chang MH; Lee IK; Si Y; Lee KS; Woo IS; Byun JH
Cancer Chemother Pharmacol; 2011 Aug; 68(2):317-23. PubMed ID: 20972872
[TBL] [Abstract] [Full Text] [Related]
15. NRAS mutations are rare in colorectal cancer.
Irahara N; Baba Y; Nosho K; Shima K; Yan L; Dias-Santagata D; Iafrate AJ; Fuchs CS; Haigis KM; Ogino S
Diagn Mol Pathol; 2010 Sep; 19(3):157-63. PubMed ID: 20736745
[TBL] [Abstract] [Full Text] [Related]
16. Epidermal growth factor receptor gene copy number in 101 advanced colorectal cancer patients treated with chemotherapy plus cetuximab.
Campanella C; Mottolese M; Cianciulli A; Torsello A; Merola R; Sperduti I; Melucci E; Conti S; Diodoro MG; Zeuli M; Paoletti G; Cognetti F; Garufi C
J Transl Med; 2010 Apr; 8():36. PubMed ID: 20398370
[TBL] [Abstract] [Full Text] [Related]
17. Insulin-like growth factor 1 expression correlates with clinical outcome in k-ras wild type colorectal cancer patients treated with cetuximab and irinotecan.
Scartozzi M; Mandolesi A; Giampieri R; Pierantoni C; Loupakis F; Zaniboni A; Galizia E; Giustini L; Silva RR; Bisonni R; Berardi R; Biagetti S; Menzo S; Falcone A; Bearzi I; Cascinu S
Int J Cancer; 2010 Oct; 127(8):1941-7. PubMed ID: 20099280
[TBL] [Abstract] [Full Text] [Related]
18. Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in k-ras wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis.
Scartozzi M; Bearzi I; Mandolesi A; Pierantoni C; Loupakis F; Zaniboni A; Negri F; Quadri A; Zorzi F; Galizia E; Berardi R; Biscotti T; Labianca R; Masi G; Falcone A; Cascinu S
BMC Cancer; 2009 Aug; 9():303. PubMed ID: 19712476
[TBL] [Abstract] [Full Text] [Related]
19. Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of k-ras in metastatic colorectal cancer patients treated with single-agent cetuximab.
Lurje G; Nagashima F; Zhang W; Yang D; Chang HM; Gordon MA; El-Khoueiry A; Husain H; Wilson PM; Ladner RD; Mauro DJ; Langer C; Rowinsky EK; Lenz HJ
Clin Cancer Res; 2008 Dec; 14(23):7884-95. PubMed ID: 19047118
[TBL] [Abstract] [Full Text] [Related]
20. Molecular detection of APC, K- ras, and p53 mutations in the serum of colorectal cancer patients as circulating biomarkers.
Wang JY; Hsieh JS; Chang MY; Huang TJ; Chen FM; Cheng TL; Alexandersen K; Huang YS; Tzou WS; Lin SR
World J Surg; 2004 Jul; 28(7):721-6. PubMed ID: 15185002
[TBL] [Abstract] [Full Text] [Related]
[Next]
